Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anteris Technologies Global Corp. ( (AVR) ) has shared an announcement.
On November 26, 2025, Anteris Technologies Global Corp. announced it would not renew its Supply and License Agreement with 4C Medical Technologies, Inc., which involved the supply of ADAPT® tissue for medical devices. This decision, effective June 1, 2026, will not incur early termination penalties and does not materially impact the company’s financial results.
The most recent analyst rating on (AVR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
Spark’s Take on AVR Stock
According to Spark, TipRanks’ AI Analyst, AVR is a Neutral.
Anteris Technologies’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and negative profitability. Technical analysis provides mixed signals, and valuation metrics are unattractive due to ongoing losses. The absence of earnings call data and corporate events leaves these areas unaddressed.
To see Spark’s full report on AVR stock, click here.
More about Anteris Technologies Global Corp.
Anteris Technologies Global Corp. operates in the medical technology industry, focusing on providing ADAPT® tissue used in the production of medical devices for transcatheter mitral valve and tricuspid valve regurgitation therapy.
Average Trading Volume: 197,870
Technical Sentiment Signal: Strong Sell
Current Market Cap: $168.9M
See more data about AVR stock on TipRanks’ Stock Analysis page.